Healthcare Costs Associated With Chronic Opioid Use and Fibromayalgia Syndrome

Area of Science:

• Health Economics
• Rheumatology
• Pain Management

Background:

• Fibromyalgia (FM) is a widespread pain disorder affecting millions in the US, incurring substantial healthcare costs.
• The idiopathic nature of FM presents diagnostic and treatment challenges.
• Understanding the economic burden of FM is crucial for effective healthcare management.

Purpose of the Study:

• To estimate the healthcare costs associated with a Fibromyalgia diagnosis.
• To evaluate the impact of chronic opioid use on the overall costs for patients with Fibromyalgia.
• To inform evidence-based treatment strategies for Fibromyalgia.

Main Methods:

• A case-control study design was employed using a large, nationally representative database of commercially insured patients.
• Propensity score-matched analyses compared costs between FM patients and controls, including analyses of chronic opioid users.
• Medical and prescription costs were primary outcomes, controlling for patient characteristics like comorbidities and medication use.

Main Results:

• A Fibromyalgia diagnosis showed a marginal effect on medical costs (-$83.54) and a modest increase in prescription costs ($120.31).
• Chronic opioid use in FM patients was associated with substantial increases in medical costs ($9094.05) and prescription costs ($3391.81).
• The economic impact of chronic opioid use far outweighs the direct costs of the FM diagnosis itself.

Conclusions:

• The direct healthcare cost differences between Fibromyalgia patients and controls are minimal.
• Chronic opioid therapy for Fibromyalgia is not supported by current evidence and significantly elevates patient costs.
• Clinical practice regarding opioid use in FM should be re-evaluated based on cost-effectiveness and evidence-based guidelines.